Experimental combo therapy shows promise for Tough-to-Treat lymphomas
NCT ID NCT04074746
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1/2 trial tested a new treatment for people with CD30-positive Hodgkin or non-Hodgkin lymphomas that returned or didn't respond to prior therapy. The treatment combines AFM13, an antibody that targets cancer cells, with natural killer (NK) cells from donated umbilical cord blood. The goal was to find the best dose and check for side effects, while also seeing if the combination can shrink tumors or slow cancer growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AFM13 (a monoclonal antibody) combined with natural killer (NK) cells from donated umbilical cord blood
- What this could lead to
- If it works, this could offer a new treatment option for people with certain lymphomas that have not responded to standard therapies.
- What could go wrong
- This is an early-phase trial with only 45 participants, so results may not apply to everyone. Side effects are possible, and the treatment may not work for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ANAPLASTIC LARGE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktails aim to outsmart Hard-to-Treat T-Cell lymphomas
- Two-Drug combo aims to outsmart resistant hodgkin lymphoma
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- Engineered immune cells take on tough blood cancers in early trial
- Can an old drug make immunotherapy work again for hodgkin lymphoma?
- New combo shows promise for rare blood cancer